Article History
Received: 30 August 2022
Accepted: 31 August 2022
First Online: 13 September 2022
Disclosures
: Dr. Dayyani is a consultant for Genentech/Roche, Array BioPharma, Exelixis, Eisai, QED Therapeutics, and Signatera. The remaining authors have no conflicts of interest.